A randomised double-blind, placebo-controlled phase I/IIa trial to investigate the effect of depletion of serum amyloid P component (SAP) on the immune response to DNA vaccination in healthy male volunteers

Trial Profile

A randomised double-blind, placebo-controlled phase I/IIa trial to investigate the effect of depletion of serum amyloid P component (SAP) on the immune response to DNA vaccination in healthy male volunteers

Completed
Phase of Trial: Phase I/II

Latest Information Update: 16 Jun 2016

At a glance

  • Drugs RO 638695 (Primary) ; HIV DNA vaccine; HIV vaccine
  • Indications HIV infections
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 11 Feb 2016 Planned End Date changed from 15 Oct 2015 to 30 Sep 2015 as rep[orted by United Kingdom Clinical Research Network.
    • 11 Feb 2016 Status changed from recruiting to active, no longer recruiting as reported by United Kingdom Clinical Research Network.
    • 20 Oct 2015 Accrual to date is 100% according to United Kingdom Clinical Research Network.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top